Clinical Study

Differential IL-13 Production by Small Intestinal Leukocytes in Active Coeliac Disease versus Refractory Coeliac Disease

Table 2

Patient characteristics of RCDII patients.

SexAge, yrsMarshTreatmentLast treatment < 6 weeks before biopsyAberrant cells, % of CD45Symbol Figures  1 and 2d

1aM68.1IIIaChemotherapy, entocortYes77%
2cM76.0IIIa2x cladribineYes37%
3F72.8IIIaCladribineNo70%
4F41.7IIIbNoneNo87%
5bF54.9IIIc6-TGYes0.6%
6M70.3ICladribine, SCTNo13%
7cM76.20CladribineYes41%
8M72.9ISCTNo73%
9M70.6ICladribineNo66%

aRCDII after successful treatment of enteropathy-associated T cell lymphoma.
bEnteropathy-associated T cell lymphoma was diagnosed when biopsy was taken.
cPatients 2 and 7 are the same patients before and after histological recovery.
6-TG: 6-thioguanine, SCT: stem cell transplantation.
dCorresponding symbol in Figures  1 and 2.